- Two cases of telbivudine-induced myopathy in siblings with chronic hepatitis B
-
Kim EH, Park H, Lee KH, Ahn SH, Kim SM, Han KH
- KMID: 1493579
- Clin Mol Hepatol.
- 2013 Mar;19(1):82-86.
- doi: 10.3350/cmh.2013.19.1.82
Telbivudine is an L-nucleoside analogue with potent antiviral activity against hepatitis B virus (HBV). Clinical trials have shown that telbivudine has a more potent and sustained antiviral activity with a... -
- CITED
-
- Close
- SHARE
-
- Close
- The assessment of hepatocellular carcinoma risk in patients with chronic hepatitis B under antiviral therapy
-
Varbobitis I, Papatheodoridis GV
- KMID: 2373131
- Clin Mol Hepatol.
- 2016 Sep;22(3):319-326.
- doi: 10.3350/cmh.2016.0045
Hepatocellular carcinoma (HCC) is a primary concern for patients with chronic hepatitis B (CHB). Antiviral therapy has been reasonably the focus of interest for HCC prevention, with most studies reporting... -
- CITED
-
- Close
- SHARE
-
- Close
- Recent trends in the treatment of chronic hepatitis C
-
Jun DW, Tak WY, Bae SH, Lee YJ
- KMID: 1372647
- Korean J Hepatol.
- 2012 Mar;18(1):22-28.
- doi: 10.3350/kjhep.2012.18.1.22
Pegylated interferon and ribavirin combination therapy is accepted as the standard antiviral treatment for chronic hepatitis C regardless of HCV genotype. This combination therapy achieves higher response rates than previous... -
- CITED
-
- Close
- SHARE
-
- Close
- Acute pancreatitis associated with pegylated interferon-alpha-2a therapy in chronic hepatitis C
-
Choi JW, Lee JS, Paik WH, Song TJ, Kim JW, Bae WK, Kim KA, Kim JG
- KMID: 2363035
- Clin Mol Hepatol.
- 2016 Mar;22(1):168-171.
- doi: 10.3350/cmh.2016.22.1.168
Chronic hepatitis C virus (HCV) infection is a major cause of liver cirrhosis and hepatocellular carcinoma. Combination therapy of pegylated interferon-alpha (PEG-IFN-α) and ribavirin (RBV) is a current standard treatment... -
- CITED
-
- Close
- SHARE
-
- Close
- Highly effective peginterferon alpha-2a plus ribavirin combination therapy for chronic hepatitis C in hemophilia in Korea
-
Yang SY, Lee HW, Lee YJ, Park SJ, Yoo KY, Kim HJ
- KMID: 2164362
- Clin Mol Hepatol.
- 2015 Jun;21(2):125-130.
- doi: 10.3350/cmh.2015.21.2.125
BACKGROUND/AIMS: Chronic hepatitis C (CHC) is a major comorbidity in patients with hemophilia. However, there are no published data on the efficacy of antiviral therapy in Korea. We assessed the... -
- CITED
-
- Close
- SHARE
-
- Close
- Sofosbuvir-based therapy for patients with chronic hepatitis C: Early experience of its efficacy and safety in Korea
-
Cho Y, Cho EJ, Lee JH, Yu SJ, Yoon JH, Kim YJ
- KMID: 2359817
- Clin Mol Hepatol.
- 2015 Dec;21(4):358-364.
- doi: 10.3350/cmh.2015.21.4.358
BACKGROUND/AIMS: The previous standard treatment for chronic hepatitis C (CHC) patients, comprising a combination of pegylated interferon (IFN) and ribavirin, was associated with suboptimal efficacy and severe adverse reactions. A... -
- CITED
-
- Close
- SHARE
-
- Close
- Tenofovir disoproxil fumarate monotherapy for nucleos(t)ide-naive chronic hepatitis B patients in Korea: data from the clinical practice setting in a single-center cohort
-
Ahn SS, Chon YE, Kim BK, Kim SU, Kim DY, Ahn SH, Han KH, Park JY
- KMID: 2069762
- Clin Mol Hepatol.
- 2014 Sep;20(3):261-266.
- doi: 10.3350/cmh.2014.20.3.261
BACKGROUND/AIMS: This study assessed the antiviral efficacy and safety of tenofovir disoproxil fumarate (TDF) for up to 12 months in Korean treatment-naive chronic hepatitis B (CHB) patients. METHODS: A total of... -
- CITED
-
- Close
- SHARE
-
- Close
- Efficacy and safety of daclatasvir plus asunaprevir for Korean patients with HCV genotype Ib infection: a retrospective multi-institutional study
-
Cho BW, Kim SB, Song IH, Lee SH, Kim HS, Lee TH, Kang YW, Kim SH, Lee BS, Chae HB
- KMID: 2412114
- Clin Mol Hepatol.
- 2017 Mar;23(1):51-56.
- doi: 10.3350/cmh.2016.0053
BACKGROUND/AIMS: The combination of daclatasvir (DCV) and asunaprevir (ASV) has demonstrated a high sustained virologic response at 12 weeks (SVR12) and a low rate of adverse events in previous clinical... -
- CITED
-
- Close
- SHARE
-
- Close
- A 2015 roadmap for the management of hepatitis C virus infections in Asia
-
Lim SG, Dan YY
- KMID: 2366001
- Korean J Intern Med.
- 2015 Jul;30(4):423-433.
- doi: 10.3904/kjim.2015.30.4.423
The prevalence of hepatitis C virus (HCV) in Asia is 0.5% to 4.7%, with three different genotypes predominating, depending on the geographic region: genotype 1b in East Asia, genotype 3... -
- CITED
-
- Close
- SHARE
-
- Close
- Clinical efficacy and safety of the combination therapy of peginterferon alpha and ribavirin in cirrhotic patients with HCV infection
-
Cheong HR, Woo HY, Heo J, Yoon KT, Kim DU, Kim GH, Kang DH, Song GA, Cho M
- KMID: 1782219
- Korean J Hepatol.
- 2010 Mar;16(1):38-48.
- doi: 10.3350/kjhep.2010.16.1.38
BACKGROUND/AIMS: The combination therapy of peginterferon (PEG-IFN) and ribavirin is the standard treatment for hepatitis C virus (HCV) infection. However, few trials have involved patients with cirrhosis. The purpose of... -
- CITED
-
- Close
- SHARE
-
- Close
- Efficacy and Long-Term Follow Up of Combination Therapy with Interferon Alpha and Ribavirin for Chronic Hepatitis C in Korea
-
Kim JH, Han KH, Lee KS, Park YN, Ahn SH, Chon CY, Moon YM
- KMID: 1777167
- Yonsei Med J.
- 2006 Dec;47(6):793-798.
- doi: 10.3349/ymj.2006.47.6.793
Combination therapy with interferon alpha (IFN- alpha) and ribavirin for 24 or 48 weeks according to HCV genotype has improved the overall sustained virological response (SVR) rates to approximately 40%.... -
- CITED
-
- Close
- SHARE
-
- Close
- Long-term efficacy of tenofovir disoproxil fumarate therapy after multiple nucleos(t)ide analogue failure in chronic hepatitis B patients
-
Kim HJ, Cho JY, Kim YJ, Gwak GY, Paik YH, Choi MS, Koh KC, Paik SW, Yoo BC, Lee JH
- KMID: 2129661
- Korean J Intern Med.
- 2015 Jan;30(1):32-41.
- doi: 10.3904/kjim.2015.30.1.32
BACKGROUND/AIMS: The efficacy of tenofovir disoproxil fumarate (TDF) for the treatment of chronic hepatitis B (CHB) patients following prior treatment failure with multiple nucleos(t)ide analogues (NAs) is not well defined,... -
- CITED
-
- Close
- SHARE
-
- Close
- Application and Efficacy of Adefovir Dipivoxil in Hepatitis B Virus-assoicated Chronic Liver Diseases
-
Cho YK, Kim BI
- KMID: 1112185
- Korean J Gastroenterol.
- 2003 Nov;42(5):357-362.
In therapy of chronic hepatitis B, there are new and exciting developments in antivirals such as nucleotide analogues. Adefovir dipivoxil is an oral prodrug of adefovir, a nucleotide analogue of... -
- CITED
-
- Close
- SHARE
-
- Close
- Long-term virological outcome in chronic hepatitis B patients with a partial virological response to entecavir
-
Jo YJ, Kim KA, Lee JS, Kim NH, Bae WK, Song TJ, Kim JW
- KMID: 2160681
- Korean J Intern Med.
- 2015 Mar;30(2):170-176.
- doi: 10.3904/kjim.2015.30.2.170
BACKGROUND/AIMS: The clinical outcome of patients with a partial virological response (PVR) to entecavir (ETV), in particular nucloes(t)ide analogue (NA)-experienced patients, has not been thoroughly investigated. The aim of the... -
- CITED
-
- Close
- SHARE
-
- Close
- Efficacy and Safety of Long-term Lamivudine Therapy in the Patients with Decompensated Liver Cirrhosis Secondary to Hepatitis B
-
Park TW, Park YM, Bae SH, Jang JW, Nam SW, Choi JY, Yoon SK, Cho SH, Yang JM, Han NI, Ahn BM, Lee YS, Lee CD, Park DH
- KMID: 863118
- Korean J Hepatol.
- 2002 Dec;8(4):428-435.
BACKGROUND/AIMS: Lamivudine use in patients with decompensated cirrhosis B has been reported to improve the hepatic function and often delay the need for liver transplantation. In the present study,... -
- CITED
-
- Close
- SHARE
-
- Close
